{
    "ticker": "OBIO",
    "name": "Obsidian Therapeutics, Inc.",
    "description": "Obsidian Therapeutics, Inc. is a biotechnology company focused on developing advanced therapeutic solutions through its proprietary cell therapy platform. Founded in 2015, Obsidian's mission is to harness the power of genetically engineered cells to treat a wide range of diseases, including cancer and genetic disorders. The company is particularly known for its innovative work in the field of controlled gene expression, which allows for precise control over therapeutic proteins within cells. This technology has the potential to enhance the efficacy and safety of cell therapies, creating a new paradigm in the treatment of chronic and complex diseases. Obsidian is also dedicated to advancing the science of cellular and gene therapies through collaborative partnerships with academic institutions and other industry leaders. The company\u2019s pipeline includes several promising candidates, with a focus on harnessing the immune system to fight cancer and developing new treatments for rare genetic conditions. As a pioneer in the biotechnology sector, Obsidian is committed to transforming patient care through cutting-edge research and development.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.obsidiantherapeutics.com",
    "ceo": "Paul W. Billings",
    "social_media": {
        "twitter": "https://twitter.com/ObsidianThera",
        "linkedin": "https://www.linkedin.com/company/obsidian-therapeutics/"
    },
    "investor_relations": "https://ir.obsidiantherapeutics.com",
    "key_executives": [
        {
            "name": "Paul W. Billings",
            "position": "CEO"
        },
        {
            "name": "Hugh A. O'Neill",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapy",
            "products": []
        },
        {
            "category": "Gene Therapy",
            "products": []
        }
    ],
    "seo": {
        "meta_title": "Obsidian Therapeutics, Inc. | Biotechnology and Advanced Therapeutics",
        "meta_description": "Explore Obsidian Therapeutics, Inc., a leader in biotechnology focused on innovative cell and gene therapies. Learn about our mission and pipeline.",
        "keywords": [
            "Obsidian Therapeutics",
            "Biotechnology",
            "Cell Therapy",
            "Gene Therapy",
            "Cancer Treatment",
            "Genetic Disorders"
        ]
    },
    "faq": [
        {
            "question": "What is Obsidian Therapeutics known for?",
            "answer": "Obsidian Therapeutics is known for developing advanced cell and gene therapies to treat diseases, primarily cancer."
        },
        {
            "question": "Who is the CEO of Obsidian Therapeutics?",
            "answer": "Paul W. Billings is the CEO of Obsidian Therapeutics, Inc."
        },
        {
            "question": "Where is Obsidian Therapeutics headquartered?",
            "answer": "Obsidian Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are the main therapeutic areas Obsidian focuses on?",
            "answer": "Obsidian focuses on cancer treatment and rare genetic disorders through cell and gene therapies."
        },
        {
            "question": "When was Obsidian Therapeutics founded?",
            "answer": "Obsidian Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "NTLA",
        "SGMO"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}